



Department
of Health &
Social Care

Projects funded by DHSC through the UK Vaccine Network Project Phase 1.0

Last updated September 2025

The following document includes all projects that were funded by the UK Vaccine Network phase 1 (2016-2022)

Contents

Projects delivered through the Innovate UK managed Vaccine Development Competition-Stream 1	3
Projects delivered through the Innovate UK managed Vaccine Development Competition-Stream 2	4
Projects delivered through Innovate UK managed competition to develop candidate vaccines and vaccine platform technologies at the preclinical stage – Stage 1	5
Projects delivered through Innovate UK managed competition to develop candidate vaccines and vaccine platform technologies at the preclinical stage – Stage 2	8
Projects delivered through Innovate UK managed competition to develop candidate vaccines and vaccine platform technologies at the clinical stage	9
Projects delivered through Innovate UK managed competition to develop vaccines for epidemic diseases: Readiness for clinical development and regulatory submission (SBRI BRIDGING CALL)	10
Projects delivered through Engineering and Physical Sciences Research Council (EPSRC) managed Future Manufacturing Research Hub competition	12
Projects delivered through Biotechnology and Biological Sciences Research Council (BBSRC) managed ‘One Health’ competition	13

Projects delivered through National Institute for Health Research managed 'Epidemiology for Vaccinology' competition	13
Projects delivered through MRC/BBSRC Centres of Excellence, managed through the National Institute for Health Research	14

Projects delivered through the Innovate UK managed Vaccine Development Competition-Stream 1

Project Title	Lead Research Organisation	Cost
Protective efficacy and neutralisation to select an optimal Zika virus vaccine	The Jenner Institute, University of Oxford	£498,870
Differential diagnostics of haemorrhagic fevers in resource poor environments.	BG Research Ltd	£654,717
Improved Q Fever Vaccine	Mologic Ltd	£522,800
An Oral Zika Vaccine	Stabilitech Limited	£214,270
A Conditional System for Inexpensive Manufacture of Attenuated Vaccines	University of Plymouth	£156,181
Polyhedrin-encased glycoproteins as novel cold chain independent vaccines	Cell Guidance Systems	£486,701
An affordable, oral vaccine against mosquito- and sexually transmitted Zika virus	Prokarium Ltd	£394,407
LassaVacc	Public Health England (Now UK Health Security Agency)	£593,928
A Dengue/Zika Vaccine that avoids Antibody-Dependent Enhancement	Excivion Ltd.	£500,000
Room temperature stable MVA-GP pox vectored vaccine against CCHF	Nova Biopharma Technologies Ltd	£428,646

Project Title	Lead Research Organisation	Cost
Emerging Viral Vaccine Antigen Insert Consortium (EVAC)	University of Cambridge	£498,379
Development of an economically viable CCHF virus vaccine for local production	Proxima Concepts Limited	£217,428
Self-administered vaccines directed against Plague and MERS	Proxima Concepts Limited	£495,000
Development of a novel vaccine for rapid response against Plague	Oxford Vaccine Group, University of Oxford	£359,777
'Plug and Display' Virus-like Particle Platform for Rapid Response Vaccination	The Jenner Institute, University of Oxford	£394,427
Clinical Development of a Zika Vaccine Avoiding Disease Enhancement	Excivion Ltd	£2,000,000
IMPROVED Q FEVER VACCINE (DSTL, PHE, ICENI DX & MOLOGIC)	Mologic	£1,642,392

Projects delivered through the Innovate UK managed Vaccine Development Competition-Stream 2

Project Title	Lead Research Organisation	Cost
Phase I Study of a MVA based vaccine for Crimean Congo Haemorrhagic fever	The Jenner Institute, University of Oxford	£1,041,860

Project Title	Lead Research Organisation	Cost
Development of a single dose ambient temperature stable vaccine for the prevention of Zika virus	Themis Ltd	£999,180
Rapid, simple manufacture and clinical evaluation of an oral plague vaccine	Prokarium Ltd	£1,035,557
A phase I clinical trial of a Chikungunya vaccine using a single dose and no adjuvant	UK Health Security Agency	£976,757
Addressing Efficacy of a Dengue vaccine candidate in a macaque challenge model	The Jenner Institute, University of Oxford	£488,611

Projects delivered through Innovate UK managed competition to develop candidate vaccines and vaccine platform technologies at the preclinical stage – Stage 1

Project Title	Lead Research Organisation	Cost
EML-VAC: Multivalent replicon vaccine against Ebola, Marburg and Lassa viruses	Imperial College London	£492,527
Exploitation of x-ray irradiated viruses for vaccine development (focussed on Rift Valley Fever)	Public Health England (Now UK Health Security Agency)	£452,324

Project Title	Lead Research Organisation	Cost
A Novel Diagnostic for anti-Zika Antibodies to Inform Deployment of Zika Vaccines	Excivion Ltd	£500,000
Novel multivalent vaccines against haemorrhagic fevers.	The Jenner Institute, University of Oxford	£483,455
Trivalent Lassa, Ebola and Marburg viral vaccine (Tri-LEMvac)	University of Cambridge	£499,825
Validation and cGMP manufacture of a Zika and Multivalent Filovirus vaccine	Emergex Vaccines	£490,375
Development of Virus-Like Particles as vaccines against emerging viral diseases (focussed on Chikungunya and Rift Valley Fever)	Leaf Systems International Limited	£408,589
Multivalent Attenuated Vaccine against Viral and Bacterial Zoonoses in Ruminants (Developing multivalent vaccine against Rift Valley Fever and Q Fever)	University of Plymouth	£469,049
Development of a novel vaccine to protect against Q fever epidemics	Oxford Vaccine Group	£327,239
A novel livestock vaccination platform to prevent zoonotic emerging infections (focussed on Q Fever, Rift Valley Fever and CCHF)	University of Edinburgh	£208,500
Nanoparticle-based Vaccine Platform against Zika Virus Infection	Vaxinano	£499,000

Project Title	Lead Research Organisation	Cost
Development of inducible expression-inactivated Leishmania as vaccine carrier (focussed on developed a multivalent vaccine against Ebola, Marburg and Lassa)	Genefirst Ltd	£350,780
Preclinical Crimean Congo Haemorrhagic Fever Vaccine Development	The Jenner Institute, University of Oxford	£394,466
New Application of a DNA-nanorod Platform for Vaccine Development	University of Strathclyde	£476,102
Multivalent Hantavirus-Vaccine (MVA SEO-HTN: Vacc) and a ferret model of disease	Public Health England (Now UK Health Security Agency)	£499,155
Pan-filovirus T-cell Vaccine Designed as Bi-valent Conserved Region Epigraphs	The Jenner Institute, University of Oxford	£271,373
Development of a Novel Nipah Virus Pre-Fusion Protein Recombinant Vaccine.	Agri-Food and Biosciences Institute	£448,950
Preclinical PoC of multivalent vaccine agents & technology platform (focussed on vaccines for Chikungunya, Zika and Ebola)	Activirosomes UK Limited	£499,798
Using engineered gut bacteria-derived microvesicles for Plague vaccines	University of East Anglia	£499,995
Serological Vaccine Standards for Ebola, Zika and MERS	NIBSC	£499,995
Adjuvant free vaccines and companion diagnostics to control	Liverpool School of Tropical Medicine	£382,974

Project Title	Lead Research Organisation	Cost
emerging flaviviruses (focussed on Zika)		
Guillain Barre syndrome antibodies during Zika and Chikungunya vaccine trials Robin Shattock, Imperial College	Imperial College London	£271,764

Projects delivered through Innovate UK managed competition to develop candidate vaccines and vaccine platform technologies at the preclinical stage – Stage 2

Project Title	Lead Research Organisation	Cost
Clinical trial of a DIOS Trivalent Haemorrhagic Fever Vaccine (DIOS-HFVac3)	University of Cambridge	£1,999,926
Development of a novel vaccine to protect against Q fever epidemics: late stage preclinical formulation and progression to clinical trial	Oxford Vaccine Group	£1,054,907
Advancement of a cost-effective MVA-based Hantavirus vaccine (HantaVacc).	UK Health Security Agency	£2,000,000
EML-VAC: Multivalent replicon vaccine against Ebola, Marburg and Lassa viruses	Imperial College London	£1,999,713

Project Title	Lead Research Organisation	Cost
Clinical Stage multivalent vaccines against viral haemorrhagic fevers	The Jenner Institute, University of Oxford	£1,999,320
CCHF Vaccine manufacturing and First in Human Clinical Trial	The Jenner Institute, University of Oxford	£1,999,524
Serological Vaccine Standards for Emerging Diseases	NIBSC	£1,999,053

Projects delivered through Innovate UK managed competition to develop candidate vaccines and vaccine platform technologies at the clinical stage

Project Title	Lead Research Organisation	Cost
Clinical development of a new vaccine for rapid response against Plague: GMP production and phase I trial	Oxford Vaccines Group	£2,991,418
Identification & Validation of Correlate of Protection for a Chikungunya Vaccine	GreyRigge Associates Ltd	£3,000,000
Ebola vaccines: persistence of immunity & response to booster dose of MVA-EBO Z	University of Oxford	£1,209,548
A phase I study of recombinant poxvirus Zika vaccines	University of Liverpool	£4,716,257
A Nipah vaccine to eliminate porcine reservoirs and safeguard human health	The Pirbright Institute	£2,359,553
Vaccine against mosquito-borne	PepTcell Limited	£3,600,000

Project Title	Lead Research Organisation	Cost
diseases	(trading as SEEK)	
Phase Ib trial of a simple, multivalent vaccine to prevent Zika and Chikungunya	The Jenner Institute / University of Oxford	£3,463,676

Projects delivered through Innovate UK managed competition to develop vaccines for epidemic diseases: Readiness for clinical development and regulatory submission (SBRI bridging call)

Project Title	Lead Research Organisation	Cost
Oral Nipah Vaccine	IOSBIO LTD	£367,532.00
Manufacturing saRNA success	University College London	£500,000.00
HFVac4: A Quadrivalent Viral Haemorrhagic Fever Vaccine for Africa	DIOSYNVAX LTD.	£498,357.00
Phase 1b/2 study of a Modified Vaccinia Ankara vectored Zika Vaccine to assess safety in previously flavivirus exposed healthy adults.	University of Liverpool	£487,363.00
Preclinical characterization of a novel vaccine for prevention of Chikungunya	ACTIVIROSOMES LIMITED	£499,800.00
The Protein Forge	THE PROTEIN FORGE LTD	£252,273.00
Development of immune assays for CCHF to aid Phase I clinical trials	UK Health Security Agency	£425,976.00
Delivering stabilised mRNA to cells for antigen production	John Innes Centre	£499,297.00

Project Title	Lead Research Organisation	Cost
Clinical development of the new ChAdOx1 Plague vaccine: A Phase 1b trial in a target population	University of Oxford	£500,000.00
A Peptide-mRNA Vaccine for Crimean-Congo Haemorrhagic Fever (CCHF)	PHION THERAPEUTICS LTD	£499,362.00
Novel T cell-based vaccine potency assay to accelerate and improve development and manufacturing	OXFORD VACMEDIX UK LIMITED	£492,559.00
A Single-dose DNA vaccine platform to safely induce protective immunity against Zika	University of Nottingham	£462,462.00
Clinical trial assessment of a multivalent vaccine against Ebola virus	University of Oxford	£371,522.00
Rapid, accessible, globally distributed RNA vaccine manufacture on demand	BIOLOGIC TECHNOLOGIES LIMITED	£474,998.00
Development of a Nipah model of disease	UK Health Security Agency	£449,946.00
Development of a CD8 T-Cell Priming Vaccine Against Chikungunya Virus	EMERGEX VACCINES HOLDING LIMITED	£490,525.00
Development of a subunit vaccine against CCHF virus for use in low-middle income countries; completion of pre-clinical studies	OXFORD EXPRESSION TECHNOLOGIES LIMITED	£377,408.00
Pan-coronavirus vaccine	CONSERV BIOSCIENCE LIMITED	£415,262.00
International Serological Standard for Plague	Medicines and Healthcare products Regulatory Agency (MHRA)	£399,821.00
A simple, multivalent vaccine to prevent Zika and Chikungunya: progression and readiness to	University of Surrey	£497,035.00

Project Title	Lead Research Organisation	Cost
phase II trial		
GMP Manufacture of a vaccine targeting a viral haemorrhagic fever	University of Oxford	£499,937.00
A live attenuated pseudorabies virus vectored Nipah vaccine for enhanced protection in pigs	The Pirbright Institute	£332,405.00

Projects delivered through Engineering and Physical Sciences Research Council (EPSRC) managed Future Manufacturing Research Hub competition

Project Title	Lead Research Organisation	Cost
Future Vaccine Manufacturing Hub	Imperial College London	£9,422,582.79
Vax-Hub	University College London	£13,010,532.00

Projects delivered through Biotechnology and Biological Sciences Research Council (BBSRC) managed 'One Health' competition

Project Title	Lead Research Organisation	Cost
One Health and accelerating Vaccines for Ebola and Lassa (OVEL)	University of Cambridge	£1,466,336.30
Accelerated development of a safe and easily manufactured Q fever vaccine	Moredun Research Institute	£1,132,649.50
Vaccines and molecular tools for the control of the emerging bunyavirus, severe fever with thrombocytopenia syndrome phlebovirus (SFTSV)	University of Glasgow	£890,279.02
A One Health approach to pan-valent morbillivirus vaccines	University of Glasgow	£761,441.74
Bunyavirus Immunity Consortium: Delineating the immune response against CCHFV and other Nairoviruses to aid effective vaccine design	University of Oxford	£1,176,386.95

Projects delivered through National Institute for Health Research managed 'Epidemiology for Vaccinology' competition

Project Title	Lead Research Organisation	Cost
Leveraging Pathogen Sequence Data and Adaptive Designs to Improve Vaccine Trials in Emerging Epidemics in LMIC	University of Oxford	£744,463.00
Electronic Data Capture to support rapid epidemiological research and response during epidemics	London School of Hygiene and Tropical Medicine	£539,143.00
Anthropological exploration of facilitators and barriers to vaccine deployment and administration during disease outbreaks	London School of Hygiene and Tropical Medicine	£810,299.00
Vaccine Efficacy Evaluation for Priority Emerging Diseases (VEEPED)	London School of Hygiene and Tropical Medicine	£1,500,000.00
Molecular Epidemiology for Vaccination Policy (MEVACP)	University of Oxford	£662,083.00

Projects delivered through MRC/BBSRC Centres of Excellence, managed through the National Institute for Health Research

Project Title	Lead Research Organisation	Cost
Phase I studies of a novel chimpanzee adenovirus Rift Valley Fever vaccine for humans	MRC Uganda Virus Research Institute, with The Jenner Institute, University of Oxford and Pirbright Institute	£1,870,492.00
Phase I studies of a novel chimpanzee adenovirus MERS vaccine	MRC Centre for Human Immunology, University of Oxford, with The Jenner Institute, University of Oxford	£1,866,981

Project Title	Lead Research Organisation	Cost
Design, development, GMP manufacture and Phase I trials of a Zika vaccine	Centre for Virus Research, University of Glasgow with The Jenner Institute, University of Oxford	£2,466,148
Advanced development of a safe and effective CCHF vaccine for livestock and humans	Pirbright Institute and Public Health England (now UK Health Security Agency)	£3,513,598
Advanced development of a safe and effective Rift Valley Fever vaccine for livestock	Pirbright Institute with The Jenner Institute, University of Oxford and International Livestock Research Institute, Nairobi	£1,886,544
A platform for the rapid development and production of candidate vaccines, analytical and diagnostic standards by plant-based transient expression for response to global viral threats.	John Innes Centre	£1,591,073

© Crown copyright 2025

www.gov.uk/dhsc

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3.

Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

